Genetics

RepliCel Life Sciences signed a collaborative research project agreement with the University of British Columbia.

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP) signed a collaborative research project agreement with the University of British Columbia.
As quoted in the press release:

The project is designed to deliver a gene and protein expression “map” of healthy hair follicle cells expected to be critically important to improving key components of the manufacturing, regulatory, and clinical profile of RepliCel’s cell therapy products.
“We are very excited to be working with UBC on a project we’ve spent considerable time designing to mature our understanding of the cell populations we work with to improve our product manufacturing, clinical outcomes, and assays critical to regulatory approval and commercialization,” stated RepliCel President and CEO, R. Lee Buckler.
This study will examine different cell groups from human hair follicles and look for differences, and similarities, in gene and protein expression. Additionally, the project will analyze array data from select subjects who participated in RepliCel’s phase I/IIa clinical trial of its RCH-01 product in development for the treatment of androgenetic alopecia which completed earlier this year. This includes data from patients who had the best clinical hair growth response at six months and a sustained positive response at 24 months.

Click here to read the full press release.

Source: www.newswire.ca

MARKETS

Markets
TSX19028.86+167.50
TSXV623.23+5.97
DOW31097.26+321.83
S&P 5003825.33+39.95
NASD11127.85+99.11
ASX6612.60+72.70

COMMODITIES

Commodities
Gold1806.95-2.15
Silver20.00+0.02
Copper3.59-0.01
Palladium1935.20-2.30
Platinum887.00+2.99
Oil110.47+2.04
Heating Oil3.96+0.02
Natural Gas5.85+0.12

DOWNLOAD FREE REPORTS

×